Other agents targeting angiogenesis, such as the antivascular endothelial growth factor receptor-2 (VEGFR-2) antibody ramucirumab, the recombinant fusion protein aflibercept, and VEGF receptor tyrosine kinase inhibitors, are also approved for the treatment of a variety of advanced cancers.5 The gene discussed is VEGFA; the disease is cancer.